These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26362271)

  • 41. [Examination of factors influencing continuity of S-1 adjuvant chemotherapy for gastric cancer patients].
    Kawabata R; Imamura H; Kishimoto T; Hachino Y; Yasui Y; Fujino M; Fujii C; Fukunaga M; Ohzato H; Furukawa H
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1205-8. PubMed ID: 22902443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
    Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
    PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
    Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [S-1-based chemotherapy for unresectable advanced gastric cancer of the elderly or patients with renal dysfunction].
    Fujiya K; Akiyama J; Yokota E; Asayama N; Ogami T; Nakajima R; Nishimura S; Sakurai T; Nagata N; Yokoi C; Kojima Y; Kobayakawa M; Gotoda T; Shimbo T; Uemura N
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1817-20. PubMed ID: 22083189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
    Suzuki S; Honda K; Sato T; Yamazaki K; Ishikawa K
    J Chemother; 2015 Oct; 27(5):297-300. PubMed ID: 25971448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Administration of S-1 after gastrojejunostomy for unresectable gastric cancer with pyloric stenosis].
    Nishikawa K; Iwase K; Fujii M; Matsuda C; Shimada K; Hirota M; Kimura T; Wada D; Nasu S; Tanaka Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):595-8. PubMed ID: 19381030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].
    Miyazaki Y; Imamura H; Kishimoto T; Furukawa H; Ota K; Tatsuta M
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2060-2. PubMed ID: 19106523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of S-1 for gastric cancer patients with positive peritoneal lavage cytology.
    Ako E; Ohira M; Yamashita Y; Kubo N; Muguruma K; Yashiro M; Sawada T; Nakata B; Kato Y; Hirakawa K
    Hepatogastroenterology; 2008; 55(86-87):1939-42. PubMed ID: 19102427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
    Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
    Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
    Kunisaki C; Makino H; Kimura J; Takagawa R; Kanazawa A; Ota M; Kosaka T; Ono HA; Akiyama H; Endo I
    Oncology; 2015; 88(5):281-8. PubMed ID: 25591954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy.
    Shitara K; Ishiguro A; Munakata M; Wada R; Sakata Y
    Int J Clin Oncol; 2006 Oct; 11(5):367-74. PubMed ID: 17058134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer.
    Nashimoto A; Yabusaki H; Nakagawa S; Takii Y; Tsuchiya Y; Otsuo T
    Anticancer Res; 2009 Nov; 29(11):4689-96. PubMed ID: 20032421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy.
    Kim N; Park C; Park DJ; Kim HH; Kim S; Kim YJ; Kim JH; Lee JS; Bang YJ; Khwarg SI; Choung H; Lee MJ; Lee KW
    Ann Oncol; 2012 Aug; 23(8):2065-2071. PubMed ID: 22589332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
    Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current status of adjuvant chemotherapy in patients with p-Stage II and p-Stage III gastric cancer].
    Sato Y; Yajima K; Kosugi S; Muneoka Y; Ichikawa H; Hanyu T; Sakamoto K; Ishikawa T; Wakai T
    Gan To Kagaku Ryoho; 2014 Aug; 41(8):961-4. PubMed ID: 25132026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
    Yagi M; Watanabe S; Yoshino S; Hazama S; Suga T; Nakazawa S
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):457-62. PubMed ID: 20332683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.